Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. on September 2, 2021, covering the month of September 2021. The filing serves to distribute a press release regarding a clinical milestone for the Company's ApoGraftTM product.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The primary material event reported is the transplantation of the first patient in the United States using Cellect's ApoGraftTM bone marrow product. This represents a significant operational milestone in the Company's clinical development program.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" section from the accompanying press release (Exhibit 99.1). The text does not explicitly detail specific financial guidance, risks, or contingencies within the body of the Form 6-K itself, deferring to the referenced exhibit for such disclosures.
Key Facts for Investor Verification
- Verify the full text of the press release (Exhibit 99.1) for details on the patient's condition and the specific clinical trial protocol.
- Review the "Forward Looking Statements" in Exhibit 99.1 for associated risks regarding future clinical outcomes.
- Confirm the status of the Company's cash position and runway in the most recent Form 20-F or 10-Q, as this filing contains no financial data.
- Monitor subsequent filings for updates on the patient's progress and any regulatory feedback from the U.S. FDA.